Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 12/20 | 0.52 |
| ▸ | PDE4A | P27815 | 6/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13761271 | 0.92 | CCR1 (0.42) | CCR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14544296 | 0.90 | CCR1 (0.41) | CCR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13761091 | 0.87 | CCR1 (0.49) | CCR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4450672 | 0.87 | CCR1 (0.51) | CCR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1637676 | 0.83 | CCR1 (0.73) | CCR1 | |
| SCHEMBL4447197 | 0.81 | CCR1 (0.45) | CCR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13761267 | 0.79 | CCR1 (0.52) | CCR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13761266 | 0.78 | CCR1 (0.42) | CCR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1638793 | 0.78 | CCR1 (0.56) | CCR1 | |
| SCHEMBL14544292 | 0.77 | CCR1 (0.41) | CCR1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576218-B2 | 4-phenylpiperdine-pyrazole CCR1 antagonists | CHEMOCENTRYX, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2007044804-A2 | PIPERIDINE DERIVATIVES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070088036-A1 | Piperidine derivatives and methods of use | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | US | disclosed |
| WO-2007044804-A2 | PIPERIDINE DERIVATIVES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088036-A1 | Piperidine derivatives and methods of use | CCR1, CCR3, CCR4 | CCR1 1/4885PDE4A 1053/4885PDE4B 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.